Massachusetts headquartered Tesaro Inc.'s shares declined 0.10%, finishing last Friday's session at $120.16. A total volume of 2.14 million shares was traded, which was above their three months average volume of 1.13 million shares. Over the last month and the previous three months, the stock has advanced 20.29% and 29.07%, respectively. Furthermore, the Company's shares have surged 129.66% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.84% and 78.10%, respectively. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US and internationally, have a Relative Strength Index (RSI) of 61.51.
On November 03rd, 2016, TESARO reported a net loss of $101.2 million, or ($1.98) per share, for Q3 2016 compared to a net loss of $66.6 million, or ($1.66) per share, for Q3 2015. Net product revenue for the reported quarter totaled $2.8 million. License, collaboration, and other revenue for Q3 2016 totaled $0.9 million and included amortization of milestone payments and shipments of clinical materials under our license agreements with Hengrui and Janssen. As of September 30th, 2016, TESARO had approximately $647 million in cash and cash equivalents, which includes the $409 million in net proceeds from a follow-on offering of 5.3 million shares of common stock that was completed in July 2016.
On November 04th, 2016, research firm FBR & Co. reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $115 a share to $133 a share. Your complete research report on TSRO can be retrieved for free at:
On Friday, shares in Canada headquartered Aralez Pharmaceuticals Inc. ended the session flat at $3.83 with a total trading volume of 556,311 shares. The stock is trading below its 200-day moving average by 15.61%. Shares of the Company, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have an RSI of 22.30.
On October 31st, 2016, Aralez Pharmaceuticals announced that its subsidiary, Aralez Pharmaceuticals Trading DAC, has completed the acquisition of the U.S. rights to Toprol-XL® (metoprolol succinate) and its Authorized Generic (AG) from AstraZeneca. In connection with the transaction, the parties entered into a Supply Agreement pursuant to which AstraZeneca will continue to manufacture and supply Toprol-XL and the AG to Aralez Ireland for at least ten years. In accordance with terms of the asset purchase agreement, the upfront amount of $175 million was paid at closing. Aralez borrowed funds under this credit facility to replenish $25 million that was previously paid from cash on hand in connection with the recently completed ZONTIVITY® acquisition. ARLZ free report is just a click away at:
Maryland-based Rexahn Pharmaceuticals Inc.'s stock jumped 5.40%, to close the day at $0.15. A total volume of 1.62 million shares was traded, which was above their three months average volume of 987,230 shares. The Company's shares are trading 27.61% below their 50-day moving average. Additionally, shares of Rexahn Pharma, which discovers, develops, and commercializes treatments for cancer, have an RSI of 25.49.
On October 31st, 2016, Rexahn Pharmaceuticals announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent for claims related to the synthesis of its novel anti-cancer investigational drug candidate, RX-3117. RX-3117 is currently in stage 2 of a Phase Ib/IIa clinical trial in patients with metastatic pancreatic cancer. Sign up for your complimentary research report on RNN at:
Shares in California headquartered CytRx Corp. recorded a trading volume of 242,392 shares. The stock ended Friday's session at $0.43, climbing 4.90%. Shares of the Company, which operates as a biopharmaceutical research and development company specializing in oncology, are trading below their 50-day moving average by 20.79%. Furthermore, CytRx's stock has an RSI of 33.23.
On October 10th, 2016, CytRx presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas. Of the 36 evaluable patients receiving either 170mg/m2 or 250mg/m2 of aldoxorubicin plus ifosfamide and mesna, 13 of 36 (36%) achieved a partial response of the target lesion by RECIST 1.1 criteria, 22 of 36 (61%) had stable disease, and one patient had progressive disease. Register for free on Stock-Callers.com and download the latest research report on CYTR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA